|
EP0970227B1
(en)
|
1997-03-20 |
2008-01-09 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors
|
|
US6183744B1
(en)
*
|
1997-03-24 |
2001-02-06 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
|
JP3835827B2
(ja)
|
1997-05-02 |
2006-10-18 |
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ リプレゼンティッド バイ ザ セクレタリーオブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
悪性細胞に対する、ｏｎｃタンパク質を含む、免疫毒素
|
|
US7696325B2
(en)
|
1999-03-10 |
2010-04-13 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide inducing apoptosis
|
|
JP2004512262A
(ja)
|
2000-06-20 |
2004-04-22 |
アイデック ファーマスーティカルズ コーポレイション |
非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ
|
|
KR20030055274A
(ko)
|
2000-10-20 |
2003-07-02 |
츄가이 세이야꾸 가부시키가이샤 |
저분자화 트롬보포에틴 아고니스트 항체
|
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
US7321026B2
(en)
|
2001-06-27 |
2008-01-22 |
Skytech Technology Limited |
Framework-patched immunoglobulins
|
|
DE60236450D1
(de)
*
|
2001-09-26 |
2010-07-01 |
Us Health |
Mutierte anti-cd22-antikörper mit erhöhter affinität zu cd22-exprimierenden leukämiezellen
|
|
TWI379693B
(en)
*
|
2002-05-02 |
2012-12-21 |
Wyeth Corp |
Calicheamicin derivative-carrier conjugates
|
|
GB0210121D0
(en)
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
|
JP2004279086A
(ja)
|
2003-03-13 |
2004-10-07 |
Konica Minolta Holdings Inc |
放射線画像変換パネル及び放射線画像変換パネルの製造方法
|
|
EP2204385A1
(en)
|
2003-11-25 |
2010-07-07 |
The Government Of U.S.A, As Represented By Secretary, Department of Health and Human Sevices |
Pseudomonas exotoxin A mutants and uses thereof
|
|
WO2006106905A1
(ja)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
会合制御によるポリペプチド製造方法
|
|
US9493569B2
(en)
|
2005-03-31 |
2016-11-15 |
Chugai Seiyaku Kabushiki Kaisha |
Structural isomers of sc(Fv)2
|
|
EP1880027B1
(en)
|
2005-05-02 |
2014-02-19 |
Cold Spring Harbor Laboratory |
Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
|
|
EP1908482B1
(en)
|
2005-06-10 |
2017-09-06 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
|
CN101262885B
(zh)
|
2005-06-10 |
2015-04-01 |
中外制药株式会社 |
含有sc(Fv)2的药物组合物
|
|
NZ591252A
(en)
*
|
2006-03-17 |
2012-06-29 |
Biogen Idec Inc |
Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids
|
|
EP2009101B1
(en)
|
2006-03-31 |
2017-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
|
US8591889B2
(en)
|
2008-04-04 |
2013-11-26 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Human monoclonal antibodies specific for CD22
|
|
US9238878B2
(en)
|
2009-02-17 |
2016-01-19 |
Redwood Bioscience, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
|
WO2011031441A1
(en)
|
2009-08-28 |
2011-03-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Therapy with a chimeric molecule and a pro-apoptotic agent
|
|
AU2010292069B2
(en)
|
2009-09-11 |
2015-08-13 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Improved Pseudomonas Exotoxin A with reduced immunogenicity
|
|
EP3797847A1
(en)
|
2010-07-30 |
2021-03-31 |
Medlmmune, LLC |
Purified active polypeptides or immunoconjugates
|
|
RU2606016C2
(ru)
|
2011-01-14 |
2017-01-10 |
Редвуд Байосайнс, Инк. |
Меченые альдегидом полипептиды иммуноглобулина и способы их применения
|
|
AU2012228100B2
(en)
|
2011-03-17 |
2016-09-08 |
The University Of Birmingham |
Re-directed immunotherapy
|
|
JP6100764B2
(ja)
|
2011-06-09 |
2017-03-22 |
アメリカ合衆国 |
免疫原性の低いｔ細胞及び／又はｂ細胞エピトープを有するシュードモナス外毒素ａ
|
|
US8932586B2
(en)
|
2011-09-06 |
2015-01-13 |
Intrexon Corporation |
Modified forms of Pseudomonas exotoxin A
|
|
ES2656505T3
(es)
|
2011-09-16 |
2018-02-27 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Exotoxina A de Pseudomonas con epítopos de linfocitos B menos inmunogénicos
|
|
JP6267644B2
(ja)
|
2011-10-20 |
2018-01-24 |
アメリカ合衆国 |
抗ｃｄ２２キメラ抗原受容体
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
CA2878642C
(en)
*
|
2012-07-19 |
2020-12-22 |
Redwood Bioscience, Inc. |
Antibody specific for cd22 and methods of use thereof
|
|
US9920124B2
(en)
|
2012-12-20 |
2018-03-20 |
Medimmune, Llc |
Methods of producing immunoconjugates
|
|
WO2014205187A1
(en)
|
2013-06-20 |
2014-12-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor
|
|
MX382731B
(es)
|
2013-09-27 |
2025-03-13 |
Chugai Pharmaceutical Co Ltd |
Metodo para producir heteromultimeros de polipeptidos.
|
|
RU2687143C2
(ru)
|
2013-10-06 |
2019-05-07 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Модифицированный экзотоксин а псевдомонад
|
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
CN107427590B
(zh)
|
2015-02-02 |
2021-08-31 |
伯明翰大学 |
具有多个t细胞表位的靶向部分肽表位复合物
|
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
|
KR102673972B1
(ko)
|
2015-05-30 |
2024-06-10 |
몰레큘러 템플레이츠, 인코퍼레이션. |
탈면역된 시가 독소 a 서브유닛 스캐폴드 및 이를 포함하는 세포-표적화 분자
|
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
|
AU2016354009B2
(en)
|
2015-11-09 |
2021-05-20 |
R.P. Scherer Technologies, Llc |
Anti-CD22 antibody-maytansine conjugates and methods of use thereof
|
|
PT3377103T
(pt)
|
2015-11-19 |
2021-05-26 |
Revitope Ltd |
Complementação de fragmento de anticorpo funcional para um sistema de dois componentes para exterminação redirecionada de células indesejadas
|
|
WO2017115773A1
(ja)
|
2015-12-28 |
2017-07-06 |
中外製薬株式会社 |
Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
|
|
CN109071634A
(zh)
|
2016-04-26 |
2018-12-21 |
R.P.谢勒技术有限责任公司 |
抗体偶联物及其制备和使用方法
|
|
US11795235B2
(en)
|
2017-09-18 |
2023-10-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Immunotoxins with albumin binding domain
|
|
US11162079B2
(en)
|
2019-05-10 |
2021-11-02 |
The Regents Of The University Of California |
Blood type O Rh-hypo-immunogenic pluripotent cells
|
|
US20230212286A1
(en)
|
2020-06-01 |
2023-07-06 |
Innobation Bio Co., Ltd. |
Antibodies specific for cd22 and uses thereof
|
|
WO2022008688A1
(en)
|
2020-07-10 |
2022-01-13 |
F. Hoffmann-La Roche Ag |
Antibodies which bind to cancer cells and target radionuclides to said cells
|
|
CN115210262B
(zh)
*
|
2020-09-29 |
2023-07-14 |
昆明赛诺制药股份有限公司 |
人源化抗-cd22重组免疫毒素及其应用
|
|
KR102393776B1
(ko)
|
2020-12-30 |
2022-05-04 |
(주)이노베이션바이오 |
Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체
|
|
KR20230137900A
(ko)
|
2020-12-31 |
2023-10-05 |
사나 바이오테크놀로지, 인크. |
Car-t 활성을 조정하기 위한 방법 및 조성물
|
|
JP2024503027A
(ja)
|
2021-01-11 |
2024-01-24 |
サナ バイオテクノロジー，インコーポレイテッド |
Ｃｄ８標的ウイルスベクターの使用方法
|
|
CA3204291A1
(en)
|
2021-01-13 |
2022-07-21 |
F. Hoffmann-La Roche Ag |
Combination therapy
|
|
JP2024511424A
(ja)
|
2021-03-25 |
2024-03-13 |
ダイナミキュア バイオテクノロジー エルエルシー |
抗ｉｇｆｂｐ７構築物およびその使用
|
|
WO2022246293A1
(en)
|
2021-05-19 |
2022-11-24 |
Sana Biotechnology, Inc. |
Hypoimmunogenic rhd negative primary t cells
|
|
IL308097A
(en)
|
2021-05-27 |
2023-12-01 |
Sana Biotechnology Inc |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
|
US20240316198A1
(en)
|
2021-07-14 |
2024-09-26 |
Sana Biotechnology, Inc. |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
|
WO2023015217A1
(en)
|
2021-08-04 |
2023-02-09 |
Sana Biotechnology, Inc. |
Use of cd4-targeted viral vectors
|
|
EP4384598A1
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
|
AU2022325232A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified primary cells for allogeneic cell therapy
|
|
WO2023019226A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
|
WO2023019225A2
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
|
EP4384188A1
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Inducible systems for altering gene expression in hypoimmunogenic cells
|
|
EP4419117A1
(en)
|
2021-10-22 |
2024-08-28 |
Sana Biotechnology, Inc. |
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
|
|
US20240408192A1
(en)
|
2021-12-17 |
2024-12-12 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
WO2023115039A2
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
|
WO2023122337A1
(en)
|
2021-12-23 |
2023-06-29 |
Sana Biotechnology, Inc. |
Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
|
|
US20250082777A1
(en)
|
2022-01-10 |
2025-03-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
EP4472646A1
(en)
|
2022-02-01 |
2024-12-11 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
EP4473097A1
(en)
|
2022-02-02 |
2024-12-11 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023154578A1
(en)
|
2022-02-14 |
2023-08-17 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
|
CA3244101A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
MODIFIED CD47 PROTEINS AND THEIR USES
|
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
WO2024064838A1
(en)
|
2022-09-21 |
2024-03-28 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
WO2024097314A2
(en)
|
2022-11-02 |
2024-05-10 |
Sana Biotechnology, Inc. |
Methods and systems for determining donor cell features and formulating cell therapy products based on cell features
|
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
|
WO2024220560A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
WO2024220574A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
WO2024220598A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Lentiviral vectors with two or more genomes
|
|
WO2024243340A1
(en)
|
2023-05-23 |
2024-11-28 |
Sana Biotechnology, Inc. |
Tandem fusogens and related lipid particles
|
|
WO2025043172A1
(en)
|
2023-08-23 |
2025-02-27 |
Sana Biotechnology, Inc. |
Modified cd47 proteins and their uses
|
|
WO2025054202A1
(en)
|
2023-09-05 |
2025-03-13 |
Sana Biotechnology, Inc. |
Method of screening a sample comprising a transgene with a unique barcode
|
|
WO2025096757A1
(en)
|
2023-11-01 |
2025-05-08 |
Sana Biotechnology, Inc. |
Hypoimmunogenic cd22-targeted car t cells for the treatment of relapsed and/or refractory b cell lymphomas
|
|
US20250230470A1
(en)
|
2024-01-12 |
2025-07-17 |
Sana Biotechnology, Inc. |
Safety switches to control in vitro and in vivo proliferation of cell therapy products
|
|
WO2025184529A1
(en)
|
2024-03-01 |
2025-09-04 |
Sana Biotechnology, Inc. |
Viral particles with fusogen display and related compositions and methods
|